Nyxoah SA
Develops hypoglossal neurostimulation therapy for Obstructive Sleep Apnea (OSA).
NYXH | BR
Overview
Corporate Details
- ISIN(s):
- BE0974358906
- LEI:
- 5493002O1ESKZ18OXR80
- Country:
- Belgium
- Address:
- Rue Edouard Belin 12, 1435 Mont-Saint-Guibert
- Website:
- https://www.nyxoah.com/
- Sector:
- Manufacturing
Description
Nyxoah SA is a medical technology company focused on the development and commercialization of solutions for Obstructive Sleep Apnea (OSA). The company's lead product is the Genio® system, a hypoglossal neurostimulation (HNS) therapy designed for patients with moderate to severe OSA. The system features a patient-centered, leadless, and battery-free implantable stimulator. It functions by providing bilateral stimulation to the hypoglossal nerve, which controls tongue muscles, to maintain an open airway during sleep.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-20 22:30 |
2025 11 20 - Press release - Number of shares (ENG).pdf
|
English | 136.6 KB | ||
| 2025-11-20 22:30 |
2025 11 20 - Press release - Number of shares (FR).pdf
|
French | 135.6 KB | ||
| 2025-09-15 22:40 |
Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.
|
English | 10.7 KB | ||
| 2025-08-29 22:30 |
2025 08 29 - Press release - Number of shares (ENG).pdf
|
English | 522.4 KB | ||
| 2025-08-29 22:30 |
2025 08 29 - Press release - Number of shares (FR).pdf
|
French | 521.0 KB | ||
| 2025-08-18 22:10 |
ENGLISH_Q2 2025 Earnings PR_FINAL.pdf
|
English | 316.1 KB | ||
| 2025-08-18 22:10 |
FRENCH_Q2 2025 Earnings PR_FINAL.pdf
|
French | 310.1 KB | ||
| 2025-08-18 22:10 |
Q2 2025 financial report (Euronext) (ENG) (final).pdf
|
English | 800.2 KB | ||
| 2025-08-18 22:10 |
Q2 2025 financial report (Euronext) (FR) (final).pdf
|
French | 803.6 KB | ||
| 2025-08-18 22:10 |
Nyxoah Reports Second Quarter Financial and Operating Results
|
English | 55.6 KB | ||
| 2025-08-11 07:00 |
Nyxoah Announces Preliminary Results for the Second Quarter of 2025
|
English | 14.8 KB | ||
| 2025-08-08 23:30 |
Nyxoah Receives Approval from FDA for Genio System for the Treatment of Obstruc…
|
English | 12.9 KB | ||
| 2025-08-08 22:10 |
ENGLISH_FDA APPROVAL PRESS RELEASE - FINAL.pdf
|
English | 156.0 KB | ||
| 2025-08-08 22:10 |
FRENCH_FDA APPROVAL PRESS RELEASE - FINAL.pdf
|
French | 166.1 KB | ||
| 2025-07-29 22:45 |
2025 07 29 - Press release - Number of shares (ENG).pdf
|
English | 136.6 KB |
Automate Your Workflow. Get a real-time feed of all Nyxoah SA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nyxoah SA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nyxoah SA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-11-19 | Laurette Renard | Close relation | Sell | 5,000 | 39,000.00 EUR |
| 2024-09-05 | Hambrecht Jürgen | Board | Sell | 980,000 | 6,840,400.00 EUR |
| 2024-09-05 | JH Capital GmbH | Close relation | Buy | 980,000 | 6,840,400.00 EUR |
| 2024-01-25 | Tompkins Patrick | Executive member | Buy | 2,000 | 18,020.00 USD |
| 2023-12-28 | Onkelinx Bruno | Executive member | Buy | 470 | 2,035.10 EUR |
| 2023-08-18 | Moreau Loïc | Executive member | Buy | 6,427 | 48,416.52 EUR |
| 2023-08-14 | Moreau Loïc | Executive member | Buy | 3,800 | 28,697.60 EUR |
| 2023-08-11 | Moreau Loïc | Executive member | Buy | 3,000 | 21,957.60 EUR |
| 2023-07-04 | Wildman Ventures LLC | Board | Buy | 25,000 | N/A |
| 2023-07-02 | Gianello Pierre | Board | Buy | 25,000 | N/A |
Peer Companies
